Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06200207 · ClinicalTrials.gov registry record · Phase 3
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
A Phase 3 study of Heart Failure and Systemic Inflammation, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 680
- Enrollment target
- 20
- Study locations
NCT06200207: Recruiting Phase 3 study of Heart Failure and Systemic Inflammation, sponsored by Novo Nordisk A/S.
NCT06200207 is a Phase 3 study of Heart Failure and Systemic Inflammation that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 680 participants, below the 2,047-participant average among 397 other Heart Failure trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06200207, a Phase 3 study of Heart Failure and Systemic Inflammation, is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 680 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study is expected to last for up to 1 year and 4 months.
Primary Outcome
Measured as score (score on scale; range; 0-100). The KCCQ is a disease-specific health status instrument composed of 23 items that quantify the domains of physical limitation, symptoms, self-efficacy, social limitation, and health-related quality of life limitation from heart failure. The overall summary score and all domains have been independently demonstrated to be valid, reliable, and responsive to clinical change. CSS scores range from 0 to 100 and lower scores represent more severe sympto
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ziltivekimab
Study Locations (20)
Florida
- Clearwater Cardiovascular Consultants - Largo
- Clearwater Cardiovascular Consultants - Largo
- Ocala Cardiovascular Research - Ocala
- Ormond Beach Clinical Research - Ormond Beach
- St Johns Ctr Clin Rsch-St. Aug - Saint Augustine
California
- Valley Clinical Trials, Inc. - Northridge
- Valley Clinical Trials, Inc. - Northridge
- UCI Health - Orange
- South California Heart Spc - Pasadena
Alabama
- Advanced Cardiovascular, LLC - Alexander City
- Eastern Shore Rsrch Inst, LLC - Fairhope
Georgia
- GA Arrhythmia Cons & Rsch Inst - Macon
- Velocity Clin Rsrch - Savannah - Savannah
Maryland
- Maryland Cardiovascular Specialists - Baltimore - Baltimore
- MD Medical Research - Oxon Hill
Michigan
- Cardio and Vascular Assoc-CAVA - Bloomfield Hills
- Millennium Cardiology - Farmington Hills
Arkansas
- Cardiology & Medicine Clinic - Little Rock
Illinois
- Chicago Medical Research LLC - Hazel Crest
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 680 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2027-01-08 |
| Phase | Phase 3 |
What NCT06200207 shows while recruiting
NCT06200207 is an interventional study that assigns participants to a tested intervention. The registered 680 participants enrollment target is mid-sized for trials with a published cap, below the 2,047-participant average among 397 other Heart Failure trials with a reported enrollment target (67% lower).
The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06200207 names 20 study sites across 9 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06200207 about?
NCT06200207 is a clinical study titled "A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation". The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment...
What is the current status of trial NCT06200207?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 680 participants. The study started on 2024-04-01. Estimated completion is 2027-01-08.
What conditions does trial NCT06200207 study?
This clinical trial studies the following conditions: Heart Failure, Systemic Inflammation.
What interventions are being tested in trial NCT06200207?
The interventions under investigation include: Placebo (DRUG), Ziltivekimab (DRUG).
Who is sponsoring clinical trial NCT06200207?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06200207 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06200207's enrollment target sits among peer trials
680 87th of 397 higher than 311 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Home-based Cardiac Rehabilitation in Heart Failure
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RECRUITING · Phase 3
-
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03501706 · 680 participants · NA
An Assessment of Cognitive Improvement Training Among Mid-life Individuals
- NCT05626452 · 680 participants · NA
PrEP Optimization Among Women to Enhance Retention and Uptake
- NCT05753748 · 680 participants · NA
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
- NCT05952141 · 680 participants · NA
Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI